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A “Novel” Treatment for an Old ProblemNaga Venkata Pothineni, MD, Amit Bahia, MD, Freij Gobal, MD, Zubair Ahmed, MD, Barry F. Uretsky, MD,
Abdul Hakeem, MDT hrombotic lesions of saphenous venousgrafts (SVGs) are frequently encountered,and interventions may be technically fraught
with embolic complications. The following 2 cases
suggest the potential role in selected cases of novel
oral anticoagulants (NOACs) in the treatment of SVG
thrombosis to obviate the need for percutaneous
intervention (PCI):
 Case 1: A 62-year-old man with 4-vessel coronary
artery bypass graft surgery performed 9 years earlier
presented with a non–ST-segment elevation myo-
cardial infarction. Angiography showed the SVG toFIGURE 1 Right Anterior Oblique Projections of Case 1
(A) Right anterior oblique projection showing a thrombus (arrows) in th
oblique projection with resolution of SVG thrombus and widely patent S
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thrombus in its midsegment with Thrombolysis
In Myocardial Infarction ﬂow grade 3, but it
was otherwise without signiﬁcant graft disease
(Figure 1A). All other grafts were patent. The patient
was treated with low-molecular-weight heparin for
1 week, followed by dabigatran etexilate 150 mg
twice a day for 1 week. Repeat angiography after
2 weeks showed complete thrombus resolution
(Figure 1B).
 Case 2: A 67-year-old woman with 3-vessel coronary
artery bypass graft surgery 5 years earlier presented
with unstable angina. Angiography showed subtotale midportion of the saphenous venous graft (SVG). (B) Right anterior
VG.
s, Little Rock, Arkansas. The authors have reported
close.
FIGURE 2 Anteroposterior Projections of Case 2
(A) Anteroposterior projection with a large layered thrombus (arrows) in a saphenous venous graft (SVG). (B) Anteroposterior projection with
resolution of thrombus and patent SVG.
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e166occlusion of the SVG to an obtuse marginal branch
with a large layered thrombus and minimal athero-
sclerotic obstruction elsewhere in the graft
(Figure 2A). All other grafts were patent. The patient
was initiated on rivaroxaban 20 mg daily. Angiog-
raphy 4 weeks later revealed thrombus resolution
and normalization of coronary ﬂow (Figure 2B).
Acute SVG thrombosis frequently presents as
acute coronary syndrome (ACS). PCI has traditionally
been the treatment of choice for abrupt SVG throm-
botic occlusions. It carries the risk of distal emboli-
zation, no reﬂow, and periprocedural myocardial
infarction. Among pharmacological alternatives for
acute SVG thrombosis, glycoprotein IIb/IIIa antago-
nists (1) and warfarin (2) have been successfully used
as pre-PCI thrombus reduction strategies. We report
the use of NOACs as “destination therapy” without
the need for PCI for acute SVG thrombosis in thesetting of ACS. It is unclear if the thrombus resolu-
tion was spontaneous with time or secondary to
NOACs. We are also uncertain about the success rate
and patient selection for this approach. Factors that
might inﬂuence success rate include thrombus
burden, age of the graft, and presence or absence of
graft degeneration. In summary, we report the ﬁrst
use of NOACs for the treatment of acute SVG
thrombosis in the setting of ACS. This noninvasive
approach may be safe and effective in selected pa-
tients who have focal nonﬂow limiting thrombotic
SVG occlusions in the absence of signiﬁcant angio-
graphic graft disease.
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